The mutual interactions between the parallel gridconnected converters coupled through the grid impedance tend to result in a number of stability and power quality challenges. To address them, this paper proposes an active damper concept based on a low-power, high-bandwidth power converter. The basic idea behind this proposal is to dynamically adjust the grid impedance seen from the point of common coupling of the gridconnected converters, such that the potential instabilities and resonance propagation can be effectively mitigated. Simulation and laboratory tests on three parallel grid-connected converters are carried out. The results validate the stabilizing performance of the active damper.

No abstract

Background: Emerging evidence suggests that p53 participates in the regulation of tumor immunity. TP53 activation in the myeloid linage suppresses alternative (M2) macrophage polarization and attenuates tumor development and invasion. Retrospective clinical analyses suggested that MDM2 amplification is associated with hyper-progression. Targeting MDM2-p53 pathway may represent a novel strategy for reversing immunosuppression and enhancing antitumor immunity of PD-1/PD-L1 blockade. APG-115 is a potent and orally active small-molecule MDM2 protein inhibitor. Binding to MDM2 protein, APG-115 restores p53 expression, activates p53 -mediated apoptosis in tumor cells retaining wild-type p53. Preclinical studies demonstrated that APG-115 promoted the production of proinflammatory cytokines in T cells, enhanced CD4 þ T cell activation, and increased PD-L1 expression on tumor cells. Enhanced antitumor activity was demonstrated in syngeneic tumor models after APG-115 combined with PD-1 blockade. Methods: APG-115 has been evaluated as a single agent in a Phase I study in US (NCT02935907). In this study, total six dose levels (10 mg, 20 mg, 50 mg, 100 mg, 200 mg and 300 mg) have been tested. The preliminary results suggested a favorable safety and tolerability profile. APG-115 exhibited an approximately dose proportional increase in exposure in PK analyses. A Phase Ib/II study of APG-115 in combination with pembrolizumab for treatment of patients with metastatic solid tumor is ongoing. Pembrolizumab is administrated as a fixed dose of 200mg IV on d1 of a 21-d cycle. Safety, tolerability, and determination of the MTD and RP2D are primary objectives of phase Ib. Results: The second cohort (APG 115 at 100 mg) has enrolled, no DLT was observed, and evidence of antitumor activity has been observed. Biomarker studies are ongoing to identify potential selection criteria. Updated clinical data will be presented. Conclusions: This represents one of the first clinical trials to evaluate MDM2mediated resistance to immunotherapy. Clinical trial identification: NCT03611868. Legal entity responsible for the study: Ascentage Pharma Group Corp Limited.

We compare the diurnal pattern of power price for weekdays and weekends for 14 deregulated markets, and find significant differences. AU markets show low early morning prices with one or more price peaks during the day and evening. North American markets show a weekday monotonic pattern; European and New Zealand markets show a "double peak" pattern. Markets differ in the ratio of daily maximom to minimum price and of average weekday to average weekend price, and hence have a different incentive for time shifting power consuming activities within and between days. Data were filtered to remove days of high or low price excursions. In some hut not all markets both the average price and the diurnal price pattern change significantly; infrequent price excursions shape price patterns. Price shows a significant correlation to load in some but not all markets. Some deregulated markets have patterns that are consistent and predictable and encourage a customer to shape power consuming activities, while other markets show a far lower degree of consistency, and create a high incentive to hedge.

No abstract